Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 220073
Company: BRISTOL
Company: BRISTOL
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| ELIQUIS | APIXABAN | 5MG | TABLET;ORAL | Prescription | None | No | No |
| ELIQUIS | APIXABAN | 0.5MG | TABLET;ORAL | Prescription | None | No | No |
| ELIQUIS | APIXABAN | 0.15MG | SUSPENSION;ORAL | Prescription | None | No | No |
| ELIQUIS SPRINKLE | APIXABAN | 0.15MG | FOR SUSPENSION;ORAL | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 04/17/2025 | ORIG-1 | Approval | Type 3 - New Dosage Form | PRIORITY |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220073s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/220073Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/220073Orig1s000TOC.html |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 04/17/2025 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220073s000lbl.pdf |